Literature DB >> 8624461

Pulmonary involvement in lymphoma.

N Berkman1, R Breuer, M R Kramer, A Polliack.   

Abstract

Intrathoracic involvement is common in both Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). The most common manifestation is mediastinal lymphadenopathy. In HD, nodal involvement is by contiguity and usually involves the superior mediastinum, while the findings in NHL are more variable. Pulmonary parenchymal disease occurs in 38% of HD and 24% of NHL. In untreated HD, parenchymal involvement is invariably associated with mediastinal lymphadenopathy and often with widespread disease. Three distinct radiological patterns of pulmonary lymphoma are recognised: nodular, bronchovascular-lymphangitic and pneumonic-alveolar. Rarely lymphoma may be endobronchial. Pleural effusion occurs in 16% of lymphoma patients and is usually associated with disease elsewhere. It is frequently caused by lymphatic obstruction but may be due to direct pleural involvement by tumour. Chylothorax may occur in NHL but is unusual in HD. Diagnosis of intrathoracic lymphoma is by transbronchial or transthoracic biopsy or by needle aspiration of tissue or pleural fluid. The addition of immunostaining improves the diagnostic yield in equivocal cases. Treatment and prognosis vary depending on cell-type, location and extent of disease.

Entities:  

Mesh:

Year:  1996        PMID: 8624461     DOI: 10.3109/10428199609051612

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  21 in total

1.  Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.

Authors:  Hong Song; Yong Du; George Sgouros; Andrew Prideaux; Eric Frey; Richard L Wahl
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

2.  Single pleural relapse of a nasal-type extranodal natural killer/t-cell lymphoma: a case report.

Authors:  Keunmo Kim; Youngmin Oh; Sung-Nam Lim; Song-Yi Choi; Ok-Jun Lee; Kang-Hyeon Choe; Ki-Man Lee; Jin-Young An
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-04-25

Review 3.  Pleural effusions in hematologic malignancies and their management with indwelling pleural catheters.

Authors:  Erik Vakil; Carlos A Jimenez; Saadia A Faiz
Journal:  Curr Opin Pulm Med       Date:  2018-07       Impact factor: 3.155

Review 4.  The radiological spectrum of pulmonary lymphoproliferative disease.

Authors:  S S Hare; C A Souza; G Bain; J M Seely; M M Gomes; M Quigley
Journal:  Br J Radiol       Date:  2012-07       Impact factor: 3.039

5.  Rapid improvement of massive bloody pleural effusion after splenectomy for splenic marginal zone lymphoma.

Authors:  Miyuki Okuda; Nobuya Tanaka; Makoto Kashio; Noriyuki Sagara; Katsuyuki Aozasa; Yoshinari Okuda; Izuo Tsuyuguchi
Journal:  BMJ Case Rep       Date:  2009-04-14

6.  Nodular sclerosing Hodgkin's lymphoma presenting with a pseudo-breast mass extending from a necrotizing granulomatous mediastinal tumor.

Authors:  Ekamol Tantisattamo; Erlaine F Bello; Jared D Acoba
Journal:  Hawaii J Med Public Health       Date:  2012-08

Review 7.  Whole-body diffusion-weighted imaging for staging malignant lymphoma in children.

Authors:  Thomas C Kwee; Taro Takahara; Malou A Vermoolen; Marc B Bierings; Willem P Mali; Rutger A J Nievelstein
Journal:  Pediatr Radiol       Date:  2010-07-30

8.  Endobronchial metastases from extrathoracic malignancies.

Authors:  Sebahat Akoglu; Eyüp S Uçan; Gülperi Celik; Gülper Sener; Can Sevinç; Oğuz Kilinç; Oya Itil
Journal:  Clin Exp Metastasis       Date:  2006-02-11       Impact factor: 5.150

Review 9.  [Lung involvement in hematologic systemic diseases].

Authors:  S-S Stecher; S Lippl; H J Stemmler; J Schreiber
Journal:  Internist (Berl)       Date:  2018-09       Impact factor: 0.743

10.  Diagnostic value of medical thoracoscopy in malignant pleural effusion induced by non-Hodgkin's lymphoma.

Authors:  Zhen Wang; Yan-Bing Wu; Li-Li Xu; Mu-Lan Jin; Xiao-Li Diao; Xiao-Juan Wang; Zhao-Hui Tong; Huan-Zhong Shi
Journal:  Oncol Lett       Date:  2017-10-19       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.